Piper Jaffray Starts Aimmune Therapeutics (AIMT) at Overweight

Piper Jaffray initiates coverage on Aimmune Therapeutics (NASDAQ: AIMT) with a Overweight rating and a price target of $35.00, leading data in peanut allergy.

Analyst Charles Duncan commented, "Aimmune is leveraging its broadly applicable oral immunotherapy (OIT) platform to develop proprietary products aimed at protecting patients with potentially life-threatening food allergies. We have evaluated the company's OIT platform and Phase II data in peanut versus other approaches such as skin patches or non-standardized "DIY" protocols. In our view, Aimmune's platform is superior based on its efficacy-driving immunomodulatory activity, on safety, and on patient-friendly product formulation that maintains high involvement with the prescribing allergist."

The analyst added, "Our valuation is based on lead candidate AR101 for peanut allergy to enter Phase III in 1Q16; we model 2025 revenues of $1.4B in the US and EU. With cash to last through 2017 and accomplished management, we believe Aimmune is poised to drive a paradigm shift in the standard for high-impact food allergies, and create substantial stakeholder value."

For an analyst ratings summary and ratings history on Aimmune Therapeutics click here. For more ratings news on Aimmune Therapeutics click here.

Shares of Aimmune Therapeutics closed at $21.11 yesterday.

You May Also Be Interested In

• BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'
• Ameriprise Financial (AMP) PT Raised to $445 at Morgan Stanley
• Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'